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Abstract
Background: Classical swine fever (CSF) caused by CSF virus (CSFV) is highly contagious andcauses significant
economic losses in the pig industry throughout the world. Previously we demonstrated that porcine Mx1 (poMx1),
when fused to HIV Tat protein transduction domain (PTD), inhibits CSFV propagation in PK-15 cells, but it is
unknown whether PTD-poMx1 exhibits antiviral activity in other porcine lines and it is efficacious for controlling
CSFV infection in pigs in China.
Methods: Two porcine cell lines, ST and 3D4/21, were used to investigate in vitro antiviral activity of PTD-poMx1
against CSFV using confocal microscopy, western blot, flow cytometry, and real-time RT-PCR. Furthermore, in vivo
antiviral activity of PTD-poMx1 was assessed by means of rectal temperature, clinical score, pathological lesion,
white blood cell count, viral load, etc.
Results: PTD-poMx1 entered both cell lines within 3 h and maintained for 16 h, but did not affect CSFV binding
and uptake. Viral titers and qRT-PCR data showed that PTD-poMx1 inhibited CSFV replication in both cell lines,
showing significant antiviral activity after infection. Injection of PTD-poMx1 into CSFV-challenged pigs attenuated
CSFV symptoms and viremia in dose-dependent manner but did not completely block virus replication within 14
days post challenge, suggesting that PTD-poMx1 confers partial protection against a lethal challenge.
Conclusion: We demonstrated the anti-CSFV activity of PTD-poMx1 in vitro and in vivo. The results have shown
that treatment with PTD-poMx1 alleviated symptoms and viral load in infected pigs. The results support our
previous in vitro studies and suggest that PTD-poMx1 could be promising in reducing the clinical signs caused by
CSFV.
Keywords: Porcine Mx1 fused to HIV Tat-PTD (PTD-poMx1), Classical swine fever virus (CSFV), Antiviral activity, in
vitro, in vivo
Background
Classical swine fever (CSF) is caused by CSF virus
(CSFV), a small, enveloped, positive-strand RNA virus of
the genus Pestivirus within the family Flaviviridae [1, 2].
CSF is acute and highly contagious in swine and is re-
sponsible for severe economic losses in pig production
worldwide [3]. Although live attenuated vaccines, includ-
ing C strain, are still used to inoculate animals for CSF
control [4], the inability to serologically differentiate vac-
cinated from infected pigs has resulted in the ban of
prophylactic vaccination in the European Union (EU)
[5]. The CP7_E2alf marker vaccine, a pestivirus chimera,
may be a suitable substitute for controlling CSF out-
breaks along with improved diagnostic tools; but the
complete protection and immune response conferred by
this vaccine needs further study in domestic pigs and sus
scrofa [6–8]. Because vaccination alone has not been suf-
ficient to control CSF, novel antiviral agents will supple-
ment current vaccine control strategies [9].
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Mx proteins are interferon-induced dynamin-like
GTPases that are present in all vertebrates [10–12], and
have a broad range of antiviral activities [13, 14]. The full-
length porcine Mx1 (poMx1) gene was first isolated from
the German Landrace breed [15] and mapped to
chromosome 13 [16]. Functional poMx1 is located in
the cytoplasm of target cells and exhibits antiviral activity
against some RNA viruses. Previous studies showed that
poMx1 confers resistance to vesicular stomatitis virus
[17, 18] and influenza virus [19, 20], suggesting that
poMx1 is an important determinant of the IFN-induced
antiviral activity. In earlier studies, we noted that EGFP-
poMx1 fusion protein overexpressing in PK-15 cells had
anti-CSFV activity, and also reported that poMx1 fused to
the protein transduction domain (PTD) of HIV [17] inhib-
ited CSFV replication in a dose-dependent manner [21].
Our previous results showed that PTD-poMx1 expressing
in E.coil inhibits CSFV propagation in PK-15 cells, sug-
gesting that PTD-poMx1 harbors the preventive effect
or the therapeutic effect. However, many details are to
be expounded as follows: i) How long the exogenous
PTD-poMx1 enters the porcine line. ii) How long it can
stay in cells after entering. iii) Whether the receptor on
the cell surface can be affected due to the exogenous
PTD-poMx1, interfering CSFV binding or uptake. More
importantly, which step in CSFV lifecycle is inhibited
by PTD-poMx1. To address these questions, porcine
cell lines (ST and 3D4/21) were used here to evaluate
the antiviral activity of the PTD-poMx1 fusion protein
in vitro. In addition, PTD-poMx1 was injected into
CSFV-challenged pigs to evaluate the antiviral activity
in vivo. Overall, our data demonstrated that PTD-poMx1
has anti-CSFV activity in vitro and in vivo, suggesting
the feasibility of a preliminary clinical application of
PTD-poMx1 against CSF infection.
Methods
Cells, virus and fusion protein
Swine testis cells (ST, CRL-1746) were purchased from
ATCC and propagated in Dulbecco’s Modified Eagle’s
Medium (DMEM, Gibco) supplemented with 10 % fetal
bovine serum (FBS, Invitrogen), 100 U/ml penicillin and
100 μg/ml streptomycin. Porcine alveolar macrophage
cells (3D4/21, CRL-2843) were a gift from Dr. Guoqing
Shao (Institute of Veterinary Medicine, Jiangsu Academy
of Agricultural Sciences) and were propagated in RPMI
1640 Medium supplemented with 10 % FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, and Non-Essential
Amino Acids (NEAA, Gibco). CSFV Shimen strain was
purchased from China Institute of Veterinary Drugs Con-
trol. PTD-poMx1 fusion protein was expressed in E. coli
and purified, denatured and refolded as previously de-
scribed [17]. Aliquots of purified protein were stored
at −80 °C.
Confocal microscopy
To determine the protein transduction efficiency, intern-
alization of PTD-poMx1 was assessed by confocal micros-
copy. Briefly, ST and 3D4/21 cells grown on glass coverslips
in 6-well plates were treated with 80 μg/ml PTD-poMx1
for 6, 12 and 24 h. Cells were then fixed with 4 % parafor-
maldehyde in PBS, and permeabilized with 0.2 % Triton
X-100. Cells were incubated with anti-poMx1 mAb
(1:500, ab79609, Abcam, USA) as a primary antibody
for 1 h at 37 °C. After washing three times with PBS,
cells were incubated with FITC-labeled goat anti-mouse
IgG (1:200, ab150113, Abcam, USA) as a secondary
antibody for 30 min at 37 °C. Cell nuclei were counter
stained with 4’, 6-diamidino-2-phenylindole (DAPI). Fluor-
escent images were acquired by LSM710 confocal laser
microscopy (Carl Zeiss Microimaging, Oberkochen,
Germany), and processed with Photoshop software.
Western blot analysis
The transduction efficiency and stability of PTD-poMx1
in ST and 3D4/21 cell lines were evaluated by Western
blot analysis as described previously [17]. Briefly, cells
were cultured as exponentially growing subconfluent
monolayers on 6-well plates. 80 μg/ml PTD-poMx1 was
added to the cells at 37 °C. Every hour from 1 to 6 h,
cells were washed three times with PBS and lysed in cold
lysis buffer (1 % Triton X-100, 1 mM PMSF in PBS) for
10 min. Lysates were clarified by centrifugation at 12,000 x
g for 10 min. Total cell extracts were separated by
SDS-PAGE and transferred onto nitrocellulose membrane.
PTD-poMx1 that translocated through the plasma mem-
brane [22] and accumulated in the cytoplasm [17] was de-
tected by anti-poMx1 mAb (1:1000). To assess the stability
of PTD-poMx1 in the cells, 80 μg/ml PTD-poMx1 was
added to the cells for 6 h at 37 °C. After washing three
times with PBS, cells in DMEM free from PTD-poMx1
were incubated for a further 4, 8, 12, 16, and 20 h.
Intracellular PTD-poMx1 in the cell lysates was detected
by anti-poMx1 mAb (1:1000) as previously described.
β-actin, a loading control, was detected by anti-β-actin
antibody (1:5000, No. A5441, Sigma-Aldrich, USA).
Flow cytometry
To determine if PTD-poMx1 affects CSFV entry into host
cells, CSFV adsorption at the cell surface was examined
after treatment with PTD-poMx1 using flow cytometry
and the data were analyzed with Cell Quest Pro software
(Becton Dickinson). Briefly, ST or 3D4/21 cells treated
with or without 80 μg/ml PTD-poMx1 were inoculated
with CSFV at a MOI of 5 for 1 h on ice. The infected cell
suspensions were prepared with PBS containing 0.02 %
ethylene-diaminetetraacetic acid (EDTA), and incubated
with the anti-E2 monoclonal antibody WH303 (1:100,
Veterinary Laboratories Agency, Surrey, UK) for 1 h at
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37 °C. After extensive wash, cells were treated with FITC-
labeled goat anti-mouse IgG (1:200) at 37 °C for 30 min.
Fluorescent signals on the cell surface were examined by a
flow cytometer (Becton-Dickinson) and the percentage of
positive cells was counted among 3 × 104 cells. Untreated
cells were used as a negative control.
Quantitative real-time RT-PCR (qRT-PCR)
Viral genome replication was measured by qRT-PCR as
previously described with modifications [21, 23]. Briefly,
viral RNA was extracted from each sample using TRIzol
reagent (Invitrogen, CA, USA). RNA pellets were sus-
pended in 20 μl DEPC-treated water and a RT reaction
was performed utilizing a RT reaction kit (Takara, Dalian,
China). Target primers for the NS5B gene [24] and refer-
ence primers for the GAPDH gene [25] were used to
quantify CSFV RNA. qPCR was carried out with SYBR
Green PCR master mix according to the manufacturer’s
protocol (Takara, Dalian, China). The data were analyzed
by the 2-△△Ct method, and expression of the target gene
was normalized to GAPDH mRNA levels in the same
samples [26].
In vitro anti-CSFV activity of PTD-poMx1
Initially, three experiments were performed in parallel to
investigate the antiviral activity of PTD-poMx1 against
CSFV in ST and 3D4/21 cells. In the first experiment
(treatment), cells (1.2 × 106) in 6-well plates were inocu-
lated with CSFV at a MOI of 0.01 for 2 h at 37 °C. Cells
were washed three times with PBS and maintained in
medium containing 80 μg/ml PTD-poMx1 for 48 h. In
the second experiment (prophylaxis), 80 μg/ml PTD-
poMx1 was added to the cells (1.2 × 106) for 6 h at 37 °C.
Cells were washed three times with PBS, then inoculated
with CSFV at a MOI of 0.01 for 2 h at 37 °C. Cells were
washed with PBS and maintained in medium free with
PTD-poMx1 for 48 h at 37 °C. In the third experiment,
80 μg/ml PTD-poMx1 was inoculated simultaneously with
CSFV at a MOI of 0.01 in the cells for 2 h at 37 °C. Cells
were washed three times with PBS and maintained in
medium free with PTD-poMx1 for 48 h at 37 °C. At 48 h
post infection (hpi), viruses within the cells were released
by freezing and thawing three times, and qRT-PCR was
performed to quantify viral replication.
Animal experiment design
Nine four-week-old specific-pathogen-free Large White
pigs were randomly assigned to three groups of three
animals housed in three separate rooms. Prior to exper-
iments, all pigs were examined serologically negative
for certain important pathogenic viruses, such as CSFV,
PRRSV, PCV2, FMDV, PRV, etc., using a series of com-
mercial ELISA diagnostic kits from IDEXX Laboratories,
Inc. and JBT Agency. Furthermore, all pigs were examined
pathogenic negative for the tested viruses using a series of
PCR/RT-PCR assays (data not shown). All animals were
oro-nasally challenged with 105TCID50 CSFV Shimen
strain. On the first day post challenge (1dpc), pigs in two
groups (designated as 1 dose and 3 doses group, re-
spectively) were injected with 1 mg/dose PTD-poMx1
protein via the ear vein. Pigs in the negative control
group (designated as NC group) received equivalent saline
via the ear vein. Pigs in 3 doses group were injected two
additional times with 1 mg PTD-poMx1 at 3 and 5 dpc.
Rectal temperature, clinical scores (1 point- no fever; 2
points- pyrexia +mild clinical signs; 3 points- severe clin-
ical signs, and 4 points- death) and pathological lesions
were monitored daily as previously described [27]. Blood
samples (sera and EDTA-anticoagulated blood) were col-
lected at 0, 3, 5, 7, 11, 14, and 21 dpc. White blood cell
(WBC) counts were measured using an Abacus Junior Vet
5 (Diatron Group, Budapest,Hungary). Care of laboratory
animals and animal experimentation were performed in
accordance with animal ethics guidelines and approved
protocols. All animal experiments were approved by the
Animal Ethics Committee of Nanjing Agricultural Univer-
sity, and performed in High Technology Innovation
Center of Animal Disease Control, Ministry of Agriculture,
PR China (BSL-3 condition).
Viremia detection
Two experiments were performed to evaluate viremia.
First, progeny viruses in sera were assessed using a TCID50
assay as previously described [28]. Second, viral RNA was
extracted from whole blood using the RNeasy mini kit
(Qiagen, Courtaboeuf, France), and viral load was detected
using qRT-PCR.
Enzyme-linked immunosorbent assay (ELISA)
Two ELISA assays were performed to detect anti-poMx1
antibody or anti-CSFV-E2 antibody in sera as previously
described with some modifications [29]. First, 96-well flat-
bottom plates were coated with purified PTD-poMx1 at a
concentration of 100 ng/well in coating buffer (Na2CO3/
NaHCO3, pH 9.6) at 4 °C overnight. Plates were washed 3
times with PBST, blocked with 1 % BSA in PBST at 37 °C
for 2 h, and then washed 3 times with PBST. 100 μl pig
sera (1:100) was added to each well. After incubation at
37 °C for 1 h, the plates were washed 3 times with PBST
and then incubated with HRP-labeled goat anti-pig IgG
antibody (1:5000, sc-2463, Santa Cruz, USA) at 37 °C for
1 h. After the final wash, 100 μl of fresh TMB substrate
(Sigma-Aldrich, USA) was added per well and plates
were incubated for 10 min. The reaction was stopped
by 2 M H2SO4, and optical density (OD) was mea-
sured at 450 nm using ELISA plate reader (ELX800).
Second, the antibodies to CSFV E2 in the sera were
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assessed using the IDEXX CSFV Antibody Test Kit
(IDEXX Laboratories, Inc., Maine, USA) according to the
manufacturer’s protocol.
Statistical Analysis
All data are presented as means ± standard deviation
(S.D.) as indicated. Student’s t-test was used to compare
pairs of treated or untreated groups. Statistical significance
is indicated as not significant (ns) (P > 0.05), * (P < 0.05),
and ** (P < 0.01). All statistical analyses and calculations
were performed using GraphPad Prism 5 (GraphPad
Software Inc, La Jolla, CA).
Results
Internalization and stability of PTD-poMx1
Our previous results have shown that PTD-poMx1
expressed in E.coil entered Vero cells after 5 h incubation
and maintained for 20 h in the cytoplasm. However, the
internalization and stability of PTD-poMx1 in porcine cell
line are unknown even though PTD-poMx1 can inhibit
CSFV replication in PK-15 cells. Some confusing details
are as follows: i). how long the exogenous PTD-poMx1
enters the porcine line. ii) how long it can stay after en-
tering the cells. To address these questions, a series of
experiments were performed as described previously
[17]. PTD-poMx1 was used at 80 μg/ml, a concentration
that had already been shown to be non-toxic to PK-15
cells. First, the intracellular localization of PTD-poMx1 in
ST or 3D4/21 cells was determined using immunofluores-
cence by confocal microscopy analysis. Fluorescent spots
were detected in the cytoplasm after incubation for 6 h
and increased along with incubation time (Fig. 1a, b), indi-
cating that PTD-poMx1 could efficiently penetrate cell
membranes within a few hours and localize in the cyto-
plasm. Second, the transduction efficiency of PTD-poMx1
was determined using anti-poMx1 mAb by Western blot
analysis. As shown in Fig. 1c, PTD-poMx1 was detected
in ST and 3D4/21 cells after 3 and 2 h, respectively, and
more was detected along with incubation time. These
results demonstrated that PTD-poMx1 entered both ST
Fig. 1 Internalization of PTD-poMx1 fusion protein. Intracellular localization of PTD-poMx1 fusion protein in ST cell line (a) and 3D4/21 cell line (b)
using confocal microscopy. Cells were treated with 80 μg/ml PTD-poMx1 fusion protein for 6, 12 and 24 h at 37 °C, then fixed in 4 % PFA for
15 min at room temperature after three washes with PBS. The anti-poMx1 mAb was applied as a primary antibody for 1 h at 37 °C. After washing
three times with PBS, cells were incubated with FITC-goat anti-mouse IgG as a secondary antibody for 30 min at 37 °C. Fluorescent spots attributed to
PTD-poMx1 were observed using fluorescence microscopy and recorded with a digital camera. Bar, 10 μm. c The transduction kinetics of PTD-poMx1.
ST or 3D4/21 cells were treated with 80 μg/ml PTD-poMx1 and sampled every hour for six hours. Each sample was washed three times with PBS and
lysed in cold lysis buffer for 10 min. Total cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membrane, and reacted with antibodies
to PTD-poMx1. The blot was stripped and re-probed with anti-β-actin antibody as a loading control. d The stability of PTD-poMx1. ST or 3D4/21 cells
were treated with 80 μg/ml PTD-poMx1 for 6 h at 37 °C. After washing three times with PBS, cells in DMEM free from PTD-poMx1 were incubated for
an additional 4, 8, 12, 16, and 20 h. Intracellular PTD-poMx1 in the cell lysates was detected using anti-poMx1 mAb as previously above
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and 3D4/21 cells. Another Western blot analysis was
performed to determine the stability of intracellular
PTD-poMx1 in ST or 3D4/21 cells. As shown in Fig. 1d,
PTD-poMx1 was detected in cell lysates of ST or 3D4/
21 cells up to 16 h, but not at 20 h.
PTD-poMx1 did not affect CSFV entry
Our previous studies showed that PTD-poMx1 did not
affect VSV entry into Vero cells [17], but little is known
about whether PTD-poMx1 affects adsorption, binding
or uptake of CSFV during infection of porcine cells. To
examine this more closely, flow cytometry was used to
evaluate the process of adsorption and binding of CSFV-
infected cells in the presence or absence of PTD-poMx1.
The results showed that the percentage of fluorescent
ST or 3D4/21 cells treated with PTD-poMx1 did not
decrease significantly compared to the untreated cells
(Fig. 2a, b), suggesting that treatment with PTD-poMx1
did not affect the specific entry of CSFV. Second, a
qRT-PCR assay was performed to evaluate the uptake
process. The results showed that the relative viral loads
were similar between the PTD-poMx1-treated and un-
treated cells (Fig. 2c, d), suggesting PTD-poMx1 did not
affect CSFV uptake.
In vitro evaluation of antiviral activity of PTD-poMx1
Since PTD-poMx1 did not affect virus binding and uptake,
it is possible that PTD-poMx1 manifests the anti-viral
activity after CSFV entry. To test this hypothesis, we
conducted three series experiments by infecting cells
with CSFV at MOI of 0.01 treating with PTD-poMx1 at
different time point: (i) cells were pretreated with PTD-
poMx1, followed by CSFV infection; (ii) cells were treated
with PTD-poMx1 and infected with CSFV simultaneously;
(iii) cells were infected with CSFV first, and then treated
with PTD-poMx1. Viral RNA loads were evaluated by
qRT-PCR as described above. As shown in Fig. 3, viral
RNA loads in cells treated with PTD-poMx1 either be-
fore or after CSFV infection were significantly decreased
(p < 0.05) compared to those in CSFV-infected cells with-
out PTD-poMx1 treatment. No significant change in RNA
level was observed in the cells that had been treated with
PTD-poMx1 and infected with CSFV simultaneously,
possibly because the co-inoculation time was too short
to transduce enough PTD-poMx1 into ST cells to inhibit
CSFV replication (Fig. 3). In addition, there was no
significant difference between the cells treated with
PTD-poMx1 before and after infection, suggesting that
PTD-poMX1 inhibited CSFV replication after entry.
In vivo evaluation of antiviral activity of PTD-poMx1 in
domestic pigs
Animal experiments were conducted to assess the anti-
viral activity of PTD-poMx1 in vivo, and three groups of
pigs were used. Two experimental groups (1 dose and 3
doses groups) and the negative control group (NC group)
Fig. 2 PTD-poMx1 did not inhibit CSFV entry. Virus binding to the surface of ST (a) and 3D4/21 (b) cells with or without PTD-poMx1 was determined
using flow cytometry analysis. ST or 3D4/21 cells treated with or without 80 μg/ml PTD-poMx1 were inoculated with CSFV at a MOI of 5 for 1 h on ice.
The infected cell suspensions were prepared with PBS containing 0.02 % EDTA, and incubated with the anti-E2 monoclonal antibody (WH303) for 1 h
at 37 °C. Cells were washed three times with PBS and treated with FITC-labeled goat anti-mouse IgG (1:200) at 37 °C for 30 min. Fluorescent signals on
the cell surface were detected and the percentage of positive cells was counted in a sample of 3 × 104 cells. Untreated cells were used as a negative
control. Virus uptake in the ST (c) or 3D4/21 (d) cell line with or without PTD-poMx1 was then determined using qRT-PCR. Cells were preincubated with
80 μg/ml PTD-poMx1 for 6 h and incubated with CSFV on ice for 1 h. Then, cells were washed three times with PBS and cultured for 2 h at
37 °C. Internalized viruses were quantified using qRT-PCR
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were compared after CSFV challenge. First, as shown in
Fig. 4a, the mean rectal temperature of pigs injected with
either 1 dose or 3 doses was lower than that of untreated
pigs at 2, 3, 5, and 7 dpc (p < 0.01). 3 doses group exhib-
ited a significant decrease in rectal temperature at 14 dpc
and thereafter (p < 0.05) when compared to group of 1
dose. By 16 dpc, the mean rectal temperature of any pig
injected with 3 doses group became normal, while any pig
received only 1 dose group still showed fever at 21 dpc.
Second, all three groups were assessed based on the devel-
opment of clinical signs such as loss weight gain, anorexia,
conjunctivitis, constipation, abdominal petechiae, nervous
disorders and prostration. As shown in Fig. 4b, the mean
score of pigs injected with either 1 dose or 3 doses group
was lower than that of untreated pigs since 5 dpc (p <
0.05). 3 doses group had a significantly lower score than 1
dose group since 11 dpc. Untill 18 dpc, all the pigs of NC
group had died, while any pig of 1 or 3 doses group was
alive. Furthermore, the pathological lesions verified the
clinic signs. As shown in Fig. 4c, NC group showed ser-
ious hemorrhage spots in some tissues including throat,
kidney and bladder. However, 1 dose or 3 doses group had
less hemorrhage spots along with more injected doses.
Third, as shown in Fig. 4d, a higher WBC count was ap-
parent at 5 and 14 dpc (p < 0.05) in 3 doses group when
compared to that in 1 dose or NC group. Finally, viremia
was measured using TCID50 and qRT-PCR assays. As
shown in Fig. 4e, we observed the increasing viral RNA
loads until 7 dpc in all groups, followed by a decrease.
The viral RNA load in NC group was higher than that in
other groups since 5 dpc (p < 0.05). Moreover, at 7, 11 and
14 dpc, there were significant differences between viral
RNA loads in 1 dose and 3 doses groups (p < 0.05). Also, a
TCID50 assay was performed to quantify virus progeny.
The trend was similar to that described earlier using
qRT-PCR data (Fig. 4f ). The mean viral titer of treated
pigs was reduced at 14 dpc when compared to untreated
pigs (p <0.01). Moreover, the mean viral titer of 3 doses
group was significantly less than that of 1 dose group (p <
0.05). Overall, the resulting data above suggested that
treatment with PTD-poMx1 could reduce viral loads
and the duration of viremia depending on the number
of doses.
An ELISA assay was performed to assess the negative
immune response to PTD-poMx1 in the pigs. As shown
in Fig. 5a, no pigs injected either 1 dose or 3 doses pro-
duced specific antibodies against poMx1. Even though
all the pigs of NC group died at 21 dpc, we further traced
the antibody titer of the treated pigs of 1 dose and 3 doses
groups. The results showed that the treated pigs were not
induced immune response to PTD-poMx1, suggesting
that PTD-poMx1 degraded quickly and did not induce an
immune response. Another ELISA assay was performed to
assess whether PTD-poMx1 could help the treated pigs to
induce antibodies to CSFV E2. As shown in Fig. 5b, al-
most no pigs produced the positive humoral response
against CSFV and the antibody titers were low below
cut off value. Intriguingly, the antibody titer of the treated
pigs were higher than that of the untreated pigs and the
treatment of 3 doses clearly increased the antibody level.
Discussion
This is the first report that poMx1 fusion protein can
reduce CSF infection in vivo, suggesting a preliminary
therapeutic treatment against CSF infection. Previous stud-
ies of interferon-induced Mx proteins and their antiviral
activities have typically relied on in vitro models. For
example, human MxA inhibits influenza virus in human
A459 cells [30, 31] and CSFV in both PK-15 cells and
swine fetal fibroblasts (PEF) [32]. Additionally, VSV
Fig. 3 Antiviral activity in ST (a) or 3D4/21 (b) cells in response to three different PTD-poMx1 treatments. Cells were treated with 80 μg/ml
PTD-poMx1 and 0.01 MOI CSFV as follows: (i) cells pretreated with PTD-poMx1, followed by CSFV infection; (ii) cells co-inoculated with PTD-poMx1 and
CSFV; (iii) cells infected with CSFV, then treated with PTD-poMx1. At 48 hpi, virus was released from cells by freezing and thawing three times, and
qRT-PCR was performed to evaluate viral RNA load in vitro. Experiments were performed in triplicate and data are shown as mean ± S.D.
Statistical significance is indicated as *(P < 0.05)
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replication can be inhibited by either porcine Mx1 in Vero
cells [17] or porcine Mx2 in NIH3T3 cells [33, 34]. Our
previous results have shown that overexpressing fusion
protein EGFP-poMx1 and PTD-poMx1 both inhibited
CSFV replication in PK-15 cells in a dose-dependent
manner [21]. However, many details need to be further
studied for elaborating how the exogenous PTD-poMx1
enters the porcine line, its stability after entering and
Fig. 4 In vivo antiviral activity of PTD-poMx1 in pigs. Nine four-week-old specific-pathogen-free Large White pigs were randomly assigned to three
groups of three pigs. All animals were oro-nasally challenged with the 105TCID50 Shimen strain of CSFV. On the first day post challenge (1dpc), pigs in
1 dose group and 3 doses group were injected 1 mg PTD-poMx1/dose via ear vein, while those in the negative control group (NC group) received
normal saline. Pigs in 3 doses group were injected two more times with 1 mg PTD-poMx1 at 3 and 5 dpc. Clinical parameters monitored in
experimental groups: a Rectal temperature; b Clinical score; c Pathological lesion; d White blood cell count; e Viral load in sera using qRT-PCR; f Progeny
viruses in sera using a TCID50 assay. All data were expressed as the mean (±S.D) of results obtained for the 3 pigs in each group within 3 weeks. Statistical
significance was indicated as not significant (ns) (P> 0.05), *(P< 0.05) and **(P< 0.01)
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where PTD-poMx1 interferes with viral replication in
viral life cycle. To clarify the above questions, we used
ST and 3D4/21 cells to further investigate the antiviral
details. Our resulting data illuminated these perplexing
problems as follows: (i) PTD-poMx1 transduced into
porcine cells within 3 h, then localized in the cytoplasm,
and was stable for 16 h. Even though PTD-poMx1 trans-
duced into PK-15 cells more quickly (1 h), it degraded
within 12 h (data not shown). These results indicated that
the internalization efficiency of PTD-poMx1 is different
among some cell lines. (ii) PTD-poMx1 did not affect
CSFV entry, suggesting neither did it compromise cell
surface receptors nor hinder CSFV absorption and up-
take. (iii) qRT-PCR results showed that the viral titer
was similar regardless of the treatment, which suggested
that poMx1 inhibited CSFV replication post CSFV entry
and the antiviral mechanism by which poMx1 inhibited
CSFV replication may involve direct interaction with viral
proteins but cellular proteins. This conflicted with a
previous report that poMx1 inhibited influenza A virus
replication by affecting the cellular early endosome [20].
Previous studies have revealed the antiviral mechanisms
of human MxA and murine Mx1. However, the antiviral
mechanism of porcine Mx1 against CSFV is unknown to
date. Interaction with viral nucleoprotein (NP) is the most
likely common pathway for MxA to perform its antiviral
function against RNA viruses, in particular for influenza A
virus [35, 36]. Based on their nucleotide and amino acid
sequences, porcine Mx1 and human MxA (huMxA) are
closely related (78 %) [13], suggesting that they have simi-
lar functions. Therefore, interaction of CSFV structural or
nonstructural proteins with poMx1 might contribute to
the antiviral function and need to be further identified
through a series of experiments. In addition, another
qRT-PCR assay was performed to evaluate the longevity
of the antiviral activity of PTD-poMx1 in ST and 3D4/21
cells, which proves to be a function of time. Significant dif-
ferences of viral genome copies were shown between treated
and untreated cells at 24, 48 and 72 hpi, which agrees with
the results obtained in PK-15 cells (data not shown).
CSF is an epidemic disease that threatens the pig in-
dustry worldwide, and particularly in China. Although C
strain is still considered one of the best CSFV vaccines,
it cannot be used as a prophylactic vaccine in the
European Union (EU) because it is impossible to sero-
logically differentiate vaccinated from infected pigs [5].
Fortunately, the CP7_E2alf marker vaccine is currently
used in some EU countries as a substitute for the C
strain [6, 8] but its immune effect is under evaluation.
Nevertheless, any vaccine needs time to take effect
[37] and pigs can still be infected during the period be-
tween vaccination and protection. Therefore, it is neces-
sary to develop other antiviral strategies to control CSF.
Additionally, despite a compulsory vaccination policy in
China since 2007, there are still sporadic and endemic
outbreaks in many areas [38]. As an alternative to mass
culling, other measures, especially the use of antiviral
agents, have been proposed [39–41]. Unfortunately, in
China almost no effective strategies are available to
control CSF transmission except for vaccination of un-
infected pigs and antibiotic therapy in infected pigs.
Moreover, antibiotics cannot effectively control the sec-
ondary bacterial infection because of drug resistance.
Some inhibitors such as BPIP (5-[(4-Bromophenyl)methyl]-
2-phenyl-5H-imidazo[4,5-c]pyridine) ([41, 42] and BBP
(2,6-Bis(benzimidazol-2-yl)pyridine) [9], exhibit anti-CSFV
activities because they target viral RdRp and can signifi-
cantly reduce viremia and viral load in infected pigs.
Although they are used in the EU, it is not known when
these drugs will be authorized for use in China.
Based on these considerations above and in intro experi-
ments, we tested whether PTD-poMx1 could be used in
infected pigs for CSF control as an antiviral agent. Our
data demonstrated that PTD-poMx1 could reduce CSFV
infection in domestic pigs. Fig. 5 showed that the CSFV-
challenged pigs treated with PTD-poMx1 clearly demon-
strated attenuated clinical signs and lower viral RNA loads
from 5 to 21 dpc. The data also showed that PTD-poMx1
of 3 doses, as opposed to 1 dose, conferred stronger anti-
viral activity and is associated with lighter clinical signs
Fig. 5 Specific antibody detected in sera using ELISA assay. a Antibody to PTD-poMx1; b Antibody to CSFV E2. All data were expressed as the
mean (±S.D) of results obtained for the 3 pigs in each group within 3 weeks. Statistical significance was indicated as *(P < 0.05) and **(P < 0.01)
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and lower viral loads although viremia was detected in
these pigs until 14 dpc. We speculate that a dose of higher
concentration and/or an increasing number of doses will
result in a stronger antiviral effect and more rapid de-
crease of viremia. Interestingly, the anti-poMx1 antibodies
of the treated pigs were not detected in the treated pigs
until 21 dpc, suggesting that PTD-poMx1 inhibited CSF
replication early in infection and rapidly degraded in the
pig’s body. In addition, the humoral response of the
treated and untreated pigs were almost negative and fi-
nally the protection antibodies were not induced. These
results were similar with previous report that only chal-
lenge pigs can’t be induced the positive immune response
(ref ). However, the antibody level in the treatment of
3 doses clearly increased, suggesting the treatment of
poMx1 may induce a positive immune response that
needs to be further testified.
Conclusions
In summary, we demonstrated the anti-CSFV activity of
PTD-poMx1 in vitro and in vivo. To the best of our
knowledge, this is the first report that PTD-poMx1 inhibits
CSFV infection in vivo. The results showed that treatment
with PTD-poMx1 alleviated symptoms and viral loads
in infected pigs. These data support and extend previous
studies, and indicate that PTD-poMx1 may be an effective
therapy against CSF infection in the future.
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